Clinical and Mechanistic Study of Modified Sinisan in Treating Precancerous Lesions of Digestive System Based on "Inflammation-to-Cancer Transformation"
10.13422/j.cnki.syfjx.20250994
- VernacularTitle:基于“炎-癌转化”探讨四逆散加减方治疗消化系统癌前病变临床及作用机制
- Author:
Xuhang SUN
1
;
Dandan WEI
1
;
Xin PENG
2
;
Shanshan LI
1
;
Yihan ZHAO
1
;
Fuke YAO
3
;
Shiqing JIANG
1
Author Information
1. The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China
2. Henan University of Chinese Medicine，Zhengzhou 450046，China
3. Xinxiang First People's Hospital，Xinxiang 453000，China
- Publication Type:Journal Article
- Keywords:
Sinisan;
precancerous lesion of digestive system;
inflammation-to-cancer transformation;
mechanistic study;
clinical study
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(18):221-234
- CountryChina
- Language:Chinese
-
Abstract:
Tumorigenesis， invasion， and metastasis occur in the context of a persistent inflammatory microenvironment， and a variety of inflammatory factors can lead to the development of various tumors. Guided by the thought of "preventive treatment of disease" in TCM and the concept of tertiary prevention in modern medicine， it is of great significance to effectively intervene in the inflammatory stage of the disease， interrupt disease progression， prevent the occurrence of malignant tumors， and reverse the process of "inflammation-to-cancer transformation". Sinisan， a commonly used prescription in the Treatise on Febrile Diseases， has been widely applied in the treatment of precancerous lesions of the digestive system， demonstrating considerable advantages. This article reviewed literature from the past 20 years， summarizing the application of Sinisan in precancerous lesions of the digestive system from three aspects： the exploration of its prescription-syndrome relationship， clinical application， and mechanistic study. It is found that basic syndrome indications of Sinisan include harmonizing the Earth element to promote spleen-stomach transportation and transformation， soothing the liver and nourishing the Wood element to restore the smooth flow of Qi， and regulating Yin and Yang to relieve stagnation within the system. In clinical application， Sinisan has shown significant efficacy in atrophic gastritis and precancerous conditions such as intestinal metaplasia， gastric ulcer， ulcerative colitis， esophagitis， and pancreatitis. Mechanistic studies have revealed that Sinisan can inhibit inflammatory factors and improve the inflammatory microenvironment， inhibit cell proliferation and regulate apoptosis， exhibit anti-angiogenic and antitumorigenic effects， modulate immune function， and exert antioxidant effects. These mechanisms can be achieved by regulating pathways such as nuclear factor erythroid 2-related factor 2/heme oxygenase-1 （Nrf2/HO-1）， farnesoid X receptor （FXR）/Nrf2， phosphatidylinositol 3-kinase/protein kinase B （PI3K/Akt）， Takeda G protein-coupled receptor 5/cyclic adenosine monophosphate/protein kinase A （TGR5/cAMP/PKA）， interleukin-4/signal transducer and activator of transcription 6 （IL-4/STAT6）， Janus kinase/signal transducer and activator of transcription （JAK/STAT）， RhoA/Rho-associated protein kinase （RhoA/ROCK）， and transforming growth factor-β/Smad proteins （TGF-β/Smads）， confirming Sinisan's role in reversing the inflammation-to-cancer transformation. The current research status of Sinisan in precancerous lesions of the digestive system was thoroughly examined through the above three aspects， along with the identification of limitations and areas for improvement in current research. The aim is to provide a basis and support for future in-depth research on Sinisan， promote the development of new integrated treatment models combining TCM and Western medicine for precancerous lesions， and aid in the research and development of drugs related to precancerous lesions.
